top of page
Search

Pharmacogenomics: Why the Same Drug Works Differently for Different People

  • Writer: Tarleen Chhatwal
    Tarleen Chhatwal
  • 6 days ago
  • 5 min read

Picture this: two patients are diagnosed with the same condition, prescribed the same medication at the same dose, and sent home with the same instructions. A week later, one of them is feeling significantly better. The other is in the emergency room with a dangerous reaction. Same drug. Same dose. Completely different outcomes.


This is not a medical error or a freak coincidence. It happens every day, in hospitals and pharmacies around the world. And more often than not, the explanation comes down to something neither patient had any control over: their genes.


Welcome to the world of pharmacogenomics, the scientific field that studies how your genes influence the way your body responds to drugs.


The "One-Size-Fits-All" Problem


For most of medical history, prescribing a drug has followed a predictable pattern. A doctor identifies a condition, selects a medication known to treat it, and prescribes a standard dose. If it does not work, they try something else. If side effects emerge, they adjust. This trial-and-error approach is not born out of negligence. It has simply been the best option available given the tools medicine had at its disposal.


Here is the uncomfortable truth, though. The standard dose of a drug is determined by averaging its effects across large groups of people. Your individual biology, however, is anything but average. Genetic factors can account for up to 95% of the variation in how different people respond to the same drug. Your genome (your complete set of genetic instructions) may be the single biggest factor in whether a medication helps you, harms you, or does nothing at all.


What Is Pharmacogenomics?


Pharmacogenomics combines two fields: pharmacology (the study of drugs and how they act in the body) and genomics (the study of a person's genes and how they function). Together, they help scientists and clinicians understand why identical doses of the same medication can produce wildly different outcomes in different people.


At its core, pharmacogenomics asks a simple question: given your unique genetic makeup, which drug is most likely to work for you, and at what dose?


How Your Genes Shape Your Response to Drugs


Think about what happens after you swallow a pill. Your body must absorb it, carry it through the bloodstream, break it down, use it, and eventually eliminate it. Each of these steps is governed by proteins, and those proteins are built according to instructions encoded in your genes.


Drug metabolism (the process by which the body chemically breaks down a drug) illustrates this clearly. Most drugs are processed in the liver by enzymes (proteins that speed up chemical reactions). The most important family of these enzymes is called cytochrome P450, or CYP for short.


Small differences in the DNA instructions for CYP enzymes, known as genetic variants, can dramatically change how fast or slow those enzymes work. Depending on your genetic profile, you might fall into one of several categories:


  • Poor metabolizers: Your enzymes work slowly, causing drugs to build up in your body to potentially toxic levels.

  • Normal metabolizers: Your enzymes work as expected, and standard doses are appropriate.

  • Rapid or ultra-rapid metabolizers: Your enzymes work so fast that the drug is broken down before it has a chance to take effect.


None of these categories is actually good or bad. They simply describe your biology. Even so, they carry profound implications for how your doctor should prescribe medications.


Real-World Consequences: When Genetics Get It Wrong


The Codeine Story


Few examples illustrate the stakes of pharmacogenomics as vividly as codeine, a common painkiller. Codeine itself is largely inactive. It must be converted by an enzyme called CYP2D6 into morphine (its active, pain-relieving form) inside the body. Since the CYP2D6 enzyme has over 100 known genetic variants, people metabolize codeine very differently.


For ultra-rapid metabolizers, codeine is converted into morphine so quickly and so completely that even a standard dose can produce life-threatening levels of the drug in the bloodstream. Tragically, multiple children with this genetic profile died after receiving codeine following routine tonsil surgeries. Their bodies essentially overdosed through their own accelerated drug conversion. For poor metabolizers, the situation plays out in reverse: codeine is never properly activated, and the patient experiences no pain relief at all.


Blood Thinners and Getting the Dose Right


Warfarin, one of the most widely prescribed blood thinners (a medication that reduces the blood's ability to clot), has long been considered the "poster child" of pharmacogenomics. Getting the dose right is notoriously difficult. Too little, and blood clots can still form. Too much, and dangerous internal bleeding becomes a serious risk.


Two genes, CYP2C9 and VKORC1, significantly influence how sensitive a person is to warfarin and how quickly the body clears it. Variants in these genes affect both how much medication a patient needs and how great their risk of complications may be. The U.S. Food and Drug Administration (FDA) now includes pharmacogenomic information in warfarin's prescribing label, a recognition of how seriously genetics must be weighed when managing this drug.


The Bigger Picture


Pharmacogenomics is not only about preventing bad reactions. At a larger scale, this science holds the promise of truly personalized medicine. Imagine a future where a doctor reviews your genetic profile and, with far greater confidence than is possible today, selects the medication most likely to work for you specifically, at the right dose, from the very first prescription.


That future is already beginning to take shape. As of 2018, the FDA had recognized over 350 pharmacogenomic biomarkers (measurable biological characteristics that indicate how a person may respond to a drug) linked to more than 280 approved medications, and that number has continued to grow. Genetic testing for pharmacogenomic purposes has been clinically available for over 15 years. Evidence continues to mount that using these tests leads to better patient outcomes.


Major medical institutions, including the University of California, San Francisco, have already begun integrating pharmacogenomic testing into routine clinical care. Genetic profiles are being embedded directly into electronic health records so that prescribing decisions can reflect a patient's DNA in real time.


What This Means for You


You may not need to request a genetic test at your next appointment. It is worth knowing, however, that this science exists and is becoming increasingly accessible. If you have ever struggled to find a medication that works, whether for depression, chronic pain, a heart condition, or cancer, your genes may have played a larger role than anyone realized at the time.


The era of "one size fits all" medicine is giving way to something far more precise. Pharmacogenomics is not science fiction. It is science already in practice, already saving lives, and growing more sophisticated with each passing year.


Written By: Tarleen Chhatwal


Sources

  1. Biology Insights. Pharmacogenomics: How Genes Affect Drug Response. https://biologyinsights.com/pharmacogenomics-how-genes-affect-drug-response/

  2. Paragon Genomics. Pharmacogenomics in the Real World: A Look at Top Genes Impacting Drug Response. https://www.paragongenomics.com/pharmacogenomics-in-the-real-world/

  3. MedlinePlus Genetics. What Is Pharmacogenomics? U.S. National Library of Medicine. https://medlineplus.gov/genetics/understanding/genomicresearch/pharmacogenomics/

  4. Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3531317/

  5. Lauschke VM, et al. Impact of Pharmacogenomics in Clinical Practice. NCBI/PMC. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10675377/

  6. Cleveland Clinic Journal of Medicine. Pharmacogenomics: An Evolving Clinical Tool for Precision Medicine. 2020. https://www.ccjm.org/content/87/2/91

  7. Frontiers in Pharmacology. Pharmacogenetics Testing for Poor Response to Antidepressants: A Transnosographic Case Series. 2024. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11496244/

  8. Wolters Kluwer. Pharmacogenomics: Effect of Gene Variability on Pain Management. 2020. https://www.wolterskluwer.com/en/expert-insights/pharmacogenomics-effect-of-gene-variability-on-pain-management

  9. GlobalRPH. Genomics and Personalized Medicine: New Clinical Evidence Shows 85% Better Patient Outcomes. 2025. https://globalrph.com/2025/04/genomics-and-personalized-medicine-new-clinical-evidence-shows-85-better-patient-outcomes/

  10. PMC / NCBI. Pharmacogenetic Labeling of FDA-Approved Drugs: A Regulatory Retrospective. https://pmc.ncbi.nlm.nih.gov/articles/PMC6115648/

  11. PMC / NCBI. The Future of Pharmacogenomics: Integrating Epigenetics, Nutrigenomics, and Beyond. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11677977/

 
 
 

Comments

bottom of page